Showing results (391-400 of 582) with videos related to
Sort By:
Pageof 59
International Journal of Cancer|June 15, 2019
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patientsFrancesco Sclafani, Sanna Hulkki Wilson, David Cunningham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)Alice Dewdney, David Cunningham, Josep Tabernero, et al.BJC Reports|November 8, 2024
Incidental finding of leukaemia in circulating tumour DNA- the importance of a molecular tumour boardJustin Mencel, Neha Rayarel, Paula Proszek, et al.Schizophrenia Bulletin|January 22, 2021
Adjunctive Aspirin vs Placebo in Patients With Schizophrenia: Results of Two Randomized Controlled TrialsMark Weiser, Daisy Zamora, Linda Levi, et al.Biomolecules|April 23, 2022
A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer CellsJankiben R Patel, Prasad Thangavelu, Renee M Terrell, et al.The American Journal of Psychiatry|July 29, 2017
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in SchizophreniaMichael Davidson, Jay Saoud, Corinne Staner, et al.Annals of Hematology|November 29, 2019
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trialAndrea Kühnl, Clare Peckitt, Bijal Patel, et al.Frontiers in Oncology|December 14, 2023
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patientsHazel Lote, Florentia Mousoullou, George Vlachogiannis, et al.Trials|May 29, 2020
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trialCaroline Forde, Ronan McMullan, Mike Clarke, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 18, 2020
The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapyH Jervoise N Andreyev, Amyn Lalji, Kabir Mohammed, et al.Pageof 59